Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell‐free fetal <scp>DNA</scp> screening in the USA: a cost analysis of screening strategies

15 Oct 2014

Abstract excerpt

OBJECTIVES: To determine whether implementation of primary cell-free fetal DNA (cffDNA) screening would be cost-effective in the USA and to evaluate potential lower-cost alternatives. METHODS: Three strategies to screen for trisomy 21 were evaluated using decision tree analysis: 1) a primary strategy in which cffDNA screening was offered to all patients, 2) a contingent strategy in which cffDNA screening was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Assisted Reproductive Technology and Twin Pregnancy
Share to Fetal and Pediatric Neurological Disorders
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25315699
DOI: 10.1002/uog.14693

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell‐free fetal <scp>DNA</scp> screening in the USA: a cost analysis of screening strategiesPMID 25315699Read ↗

An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy PopulationSemantic proximity Read ↗

Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysisSemantic proximity Read ↗

Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategiesSemantic proximity Read ↗

The price of performance: a cost and performance analysis of the implementation of cell‐free fetal DNA testing for Down syndrome in Ontario, CanadaSemantic proximity Read ↗

<scp>UK NHS</scp> pilot study on cell‐free <scp>DNA</scp> testing in screening for fetal trisomies: factors affecting uptakeSemantic proximity Read ↗

Clinical implementation of routine screening for fetal trisomies in the UK NHS : cell‐free DNA test contingent on results from first‐trimester combined testSemantic proximity Read ↗

The price of abandoning diagnostic testing for cell‐free fetal DNA screeningSemantic proximity Read ↗

Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions in Average-Risk Pregnancies: A Cost-Effectiveness AnalysisSemantic proximity Read ↗

The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysisSemantic proximity Read ↗

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21Semantic proximity Read ↗

A cost‐effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.